Skip to content
LifeSci Partners Podcast podcast artwork

LifeSci Partners Podcast

by LifeSci Partners.com

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

From the show's RSS feed, refreshed Oct 16, 2024. Source feed.

Subscribe Bookmark

Episodes

  1. Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry

    Tune into Episode #2 of the LifeSci Search podcast with Andy Cronin (President & Co-Founder) and Ayesha Price (Sr. Director, Executive Search) as they host Iris Grossman (Chief Therapeutics Officer, Eleven Therapeutics) and Shahram Ebadollahi (Operating Partner, ARCHIMED & Former Chief Data...

  2. LifeSci Search Podcast: Episode #1

    Tune into Episode #1 of the LifeSci Search Podcast.

  3. Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair

    In the clinical setting, the time it takes to address a serious problem can make the difference between life and death. To save as much time as possible, the necessary material – a vessel to do a coronary bypass, for example – needs to be readily available. However, due to the organic nature of...

  4. A Brief Chat with Erez Raphael, CEO of DarioHealth

    Tune into this 17-minute chat with Erez Raphael, CEO of DarioHealth (NASDAQ: DRIO).

  5. Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs

    CDK and RAS-targeting drugs already exist, but in the setting of oncology, if it’s not curative, it’s not enough. As a former practicing oncologist, Onconova’s CEO Dr. Steven Fruchtman knows this and has spent his career at the bench, and now the boardroom, working to improve and provide such…

    more
  6. A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.

    Tune into this 9-minute chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc. (NYSE: PLX).

  7. A Brief Chat with Martin Welschof, CEO of BioInvent

    Tune into this 17-minute chat with Martin Welschof, CEO of BioInvent (STO: BINV).

  8. A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.

    Tune into this 11-minute chat with Raphi Levy, CFO of Alpha Tau Medical Ltd. (NASDAQ: DRTS).

  9. A Brief Chat with Amir London, CEO of Kamada Ltd.

    In this 13-minute chat, Amir London, CEO of Kamada Ltd. (NASDAQ: KMDA), discusses the growing commercial business of the company, including six FDA-approved products for rare and serious conditions, and its innovative development pipeline, targeting areas of significant unmet medical need.

  10. A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.

    In this 15-minute chat, Rob Etherington, President & CEO of Clene, Inc. (NASDAQ: CLNN) discusses the potential for nanosuspensions to improve cellular energy production and treat neurodegenerative diseases, along with Clene’s future directions.

  11. Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound

    Repairing damage to living tissue often requires the removal or debridement of what was destroyed. This is usually done through surgery—an invasive process performed in a clinical setting that is inherently stressful for the patient. EscharEx is none of that. A topically administered biologic,...

  12. A Promising New Immune Checkpoint from Sensei Bio: VISTA

    CTLA-4 was a breakthrough; PD-1—a blockbuster, then IDO got busted and biotech retreated to the bench. It got quiet for a while, but the basic science bounced back, and now we have LAG-3, and on the horizon, a new VISTA. Myeloid cells have the target, and Sensei Bio has the drug. Tune in as CEO...

  13. Turning Amino Acids into Drugs: A Novel Platform from Axcella Health

    Endogenous metabolic modulators (EMMs) are composed of amino acids and, when given in combination, have the potential to treat serious disease. With their lead EMM compound AXA1125, a proprietary blend of amino acids, Axcella is posed to address the urgent and growing unmet needs in the settings…

    more
  14. Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders

    Drug discovery is an adventure, drug delivery is an art. The chemists at Lipocine put their experience to the test — by turning drugs with problematic administration into oral agents with improved bioavailability. With validation from their recently approved testosterone replacement drug…

    more
  15. 89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin

    As the American obesity issue grows, the NASH and SHTG treatment markets concurrently expand. At 89bio, the idea is to use nature itself to therapeutically treat this growing problem. Using their lead asset pegozafermin, an analog of the endogenous hormone fibroblast growth factor 21 (FGF21), to...

  16. De-Risked Oncology Targets with Assets from Checkpoint Therapeutics

    James Oliviero, CEO of Checkpoint Therapeutics, is certain that fortunes can be won by building better and cheaper mousetraps. That’s why he is positioned to capture significant market share with assets for the de-risked oncology targets of PD-L1, with Cosibelimab, and EGFR with Olafertinib. For...

  17. Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction

    The CEO of BrainsWay Ltd, Christopher von Jako, is committed to non-invasive medical technologies – particularly when it comes to the brain. A businessman with over 30 years of experience in medical devices and a PhD in neurology, Dr. von Jako now spearheads the continued development, sales, and...

  18. An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals

    It’s the circle of life: the cell cycle is a molecular merry-go-round for the propagation of all cells, including tumor cells. This process is regulated by cyclin-dependent kinases (CDKs), thus, CDK inhibition has long been a goal of drug developers. However, until very recently, toxicity has...

  19. Oncology on the Move—Artios: Financing Considerations for an Early Biotech

    Artios has raised eyebrows, and cash, raising $320 million since its founding in 2016. Led by CEO, Niall Martin, who spearheaded the development of the PARP inhibitor, Lynparza™, along with the scientific guidance of DDR pioneer, Dr. Graeme Smith, Artios has been able to make a scientific impact....

  20. Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

    Most oncology drugs turn things off—Alligator Bioscience prefers to turn things on, specifically, the immune system, by way of stimulation with CD40 and 4-1BB agonists. In this podcast, Alligator CEO, Søren Bregenholt, discusses the latest clinical data for lead anti-CD40 asset, mitazalimab, as...

  21. Esperion Therapeutics: A Small Company with a Big Heart

    Lowering your LDL levels—so-called “bad cholesterol”—can save your life: an irrefutable observation made possible by the advent of statins. The good news is that we have statins by the bucket-full; however, the bad news is that not everyone can tolerate statins (>20%) or they can’t hit…

    more
  22. Patient-centric, Physician-managed healthcare centers that Payers love: P3 Health Partners

    My mother, a woman who thrived on organization, always had her entire medical history in hand when she saw a new healthcare provider—both in hard copy and on disk. No one ever looked at it. Not once. They were not the records of that particular provider and therefore, did not count. And having…

    more
  23. Two Oncology Assets in the Clinic and a sought-after Discovery Platform: Ryvu Therapeutics

    Ryvu’s lead asset, discovered-inhouse is RVU120, a CDK8/19 inhibitor with activity in both hematologic and solid tumor cancers currently undergoing multicenter, international testing for AML and TNBC, respectively. With data reported as recently as EHA 2022, pivotal phase II testing will commence...

  24. Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10

    Using cytokines therapeutically is like firing a shotgun at range – for sure you will hit your target, but off-target effects are likely, if not certain. To hit your target exclusively you have to get close. Delivering a proprietary version of the chronic inflammatory cytokine IL-10 encoded on a...

  25. A Pioneer of PARP Inhibition has a New DNA Damage Repair (DDR) Platform

    An inch wide and a mile deep—that’s the sort of expertise CSO of Artios Pharma, Dr. Graeme Smith, brings his benchtop. Since his time at Cambridge, Smith has been laser focused on DDR mechanisms, first elucidating, and then translating those observations to create the PARP inhibitor drug…

    more
  26. Teclison’s cancer immunotherapy-enhancer, TEC-001, shows efficacy in all-cause hepatic tumors

    Hypoxia is the key. TEC-001 is a prodrug selectively activated in hypoxic environments, such as that induced by the long-known technique called trans-arterial embolization, a procedure that shuts off blood supply to tumors and thereby creates a low-oxygen, hypoxic environment. Delivered directly…

    more
  27. iBreathe it in: Inhalable drug delivery with the iSPERSE platform, from Pulmatrix

    A car is a very efficient delivery system until you can’t find a place to park, or the spot you find is nowhere near where you wanted to go. For medicine, getting to the right place, and getting there in time is critical. With the iSPERSE platform you can reformulate known drug entities—compounds...

  28. P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)

    MDM2 is a key regulator of p53, the protein responsible for tumor suppression and apoptosis — an intractable, yet undruggable target. Previous attempts to drug MDM2 have been met with significant toxicities issues. The MDM2 oral inhibitor milademetan has the potential to address these issues and…

    more
  29. An anti-PD-L1 Antibody Given Subcutaneously: Envafolimab, by Tracon Pharma

    The only people that like infusion suites are those who own them. Payers don’t like them. Patients hate them. But for many drugs, due to their molecular nature there is simply no choice, and this has been the case with the class of drugs known as checkpoint inhibitors—until now. Now there is...

  30. Two conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIO

    By way of an exquisite toggling of activity, HADUVIO stimulates one opioid receptor (kappa) and blocks the activity of another (mu) while avoiding the engagement of the third (delta). The objective of this combination of receptor activity is to decrease chronic cough due to Idiopathic Pulmonary...

  31. Special Delivery Platforms: pH-activated and STING activating polymeric micelles from OncoNano Medicine

    If the pandemic taught us nothings else, we’ve learned the critical importance of having a dependable system for delivery. OncoNano offers two such systems (read: platforms). The first, ON-BOARD, is a polymeric micelle that delivers its therapeutic payload only in the acidic environment of a…

    more
  32. Phase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc Voigt

    Along with the first-ever approval by the FDA of a so-called checkpoint inhibitor, the anti-CTLA-4 drug Yervoy, in 2001, came vindication; the treatment modality of immuno-oncology (IO) had arrived. Anti-PD-1 drugs soon followed with even greater—far greater impact. But then came some failures…

    more
  33. Inducing Immune Tolerance in Autoimmunity, Gene Therapy, and Beyond: The ImmTOR® Platform, from Selecta Biosciences

    There’s no point in receiving a gift you can’t keep, be it a pony, or a therapeutic. For the latter to be effective it must be retained, yet the immune system can’t discriminate between friend or foe; there is only you, and not you, and not you is simply not tolerated. Enter ImmTOR®, a…

    more
  34. Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences

    There’s nothing new about transdermal delivery of drugs—patches, gadgets, and solvents abound—but each has physical limitations, and the drugs themselves may not be amenable to a particular approach. Enter a novel drug formulation platform by Dyve Biosciences. Delivered in what appears to be a...

  35. Location, Location, Location: Delivering Your IO Asset Directly to the Lymph Node with Amphiphile

    In pharmacology, getting your drug to where it’s needed is everything. In immunology, to elicit an immune response that location is often the lymph node, and the point of delivery are antigen presenting cells. Amphiphile, from Elicio, can make that happen. Whether the cargo is DNA, a peptide, or…

    more
  36. Making sure there’s not a dry eye in the house with Tyrvaya®, from Oyster Point Pharma

    Innovation can sometimes be counterintuitive, as in the case with Tyrvaya, a drug approved in 2021 for the signs and symptoms of dry eye disease that is a nasal spray. And how does that make sense? Well, it makes sense because Tyrvaya ®, a cholinergic agonist to treat the underlying, and…

    more
  37. The sweet spot (and the market) between the adaptive & innate immune response: Allogeneic Natural Killer T cells (NKT) from Athenex

    The allure of allogeneic “off-the-shelf” adaptive cell therapy (ACT) is obvious – by definition, the treatment is immediately available, and due to the nature of batch manufacture versus the one-off creations of an autologous ACT, it will very likely be cheaper. The question remaining is what…

    more
  38. A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System

    Having focused on endocrine disorders since grad school, first at the bench and later in the board room, Dr. Thierry Abribat founded and became the CEO of EU-based Amolyt Pharma because he wanted to have a “social impact” – he wanted to make a difference. With two clinical stage, biologic assets…

    more
  39. A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.

    Everyone is excited about KRAS, the “undruggable” target that now has a drug. However, that drug only hits one specific, rather rare KRAS mutation, leaving the vast majority of patients with KRAS mutant variants who, after exhausting standard of care (SOC), are left without any effective…

    more
  40. Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene

    Hear how Jay Mei, MD, PhD, went from his benchtop years at the NIH to a blockbuster launch at Celgene (think, Revlimid, after stints at Novartis and J&J along the way) – to spearhead the multi-asset juggernaut that is the oncology company, Antengene. From it’s “license and build” beginnings, to…

    more
  41. Dyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.

    Proteins designed as drugs – the so-called biologics – sparked a medical revolution, but it has come at an extraordinary cost: less than 2% of Americans use these drugs, yet they account for 40% of total spend on prescription medications. Something’s got to give. Mark Emalfarb of Dyadic thinks…

    more
  42. Differentiated Delivery with DPX® - a Versatile Technology for Immuno-Oncology by IMV Inc.

    Having the ability to activate a precise, robust and persistent immune response to kill cancer cells is what IMV is all about. Using its DPX delivery technology, IMV’s immunotherapies are easy and cost-effective to manufacture. With promising clinical data now available, their lead compound is…

    more
  43. Developing Drugs for Rare Diseases: Pointers and Pitfalls

    There are approximately 30 million individuals in the U.S. currently living with one of at least 7,000 rare diseases. The National Organization for Rare Disorders estimates that more than 90% of these patients are still without an FDA-approved treatment. Dr. Jane Larkindale, VP of Clinical…

    more
  44. Targeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical development

    A scar is proof you survived – a good thing. Uncontrolled scarring, called fibrosis, is a threat unto itself (think cirrhosis) or an impediment to clinical intervention (think macrophages, T-cells and cancer). Mechanisms that drive both involve the molecule, Gal-3, and an enzyme, LOXL2. The…

    more
  45. Mapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer Therapy

    In oncology, the field of neoantigen prediction is rife with proprietary mathematics for homing in on the best antigens for T cell activation. Only one neoantigen platform, ATLAS, from Genocea, tells you not only about what activates, but also what antigens/epitopes suppress that T cell activity…

    more
  46. Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER

    Every cancer neoantigen prediction platform has lots and lots of math – the PIONEER platform, from the Danish company, Evaxion, has data. In a phase I/IIa study in metastatic melanoma the ORR was 67%, and two patients with stable disease converted to complete responders. Investors take note,...

  47. Water, Water, Everywhere – Innovations in Treating Diuretic-Resistant Fluid Overload: Sequana Medical

    Not enough fluids? Drink more. Too much fluid – entirely different, far more complex problem. From the systemic swelling caused by congestive heart failure to the localized ascites caused by cancer, or NASH, Sequana Medical has developed novel approaches to drain the fluid away when diuretics are...

  48. Modulation of NMDA Receptors for Pain and CNS Disorders: The Middle Way – that’s Aptinyx

    Turning a biological process on or off is like flipping a light switch. However, these approaches often come with serious side effects that can limit therapeutic utility. For this reason, treating certain types of CNS disorders like chronic pain, PTSD, and cognitive impairment requires a more...

  49. Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets

    Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients.

  50. Captor Therapeutics: Top Grades for Degrading Pathologic Proteins in Oncology and Autoimmune Disease: Captor Therapeutics

    Hear how Captor Therapeutics became a Swiss/Polish public biotech company run by a Scotsman –as told by 30-year healthcare industry veteran and Captor’s CEO, Dr. Tom Shepherd. That’s one great story – another is how Captor’s targeted protein degradation platform will stick it to the competition...

About this show

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

Hosted by

LifeSci Partners.com

Categories

Frequently asked questions

How many episodes does LifeSci Partners Podcast have?

LifeSci Partners Podcast has 74 episodes on PodParley. The most recent episode was published on October 3, 2023.

What is LifeSci Partners Podcast about?

This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.

How often does LifeSci Partners Podcast release new episodes?

LifeSci Partners Podcast publishes every two weeks, based on its 74 episodes since May 2021.

Who hosts LifeSci Partners Podcast?

LifeSci Partners Podcast is created and hosted by LifeSci Partners.com.
Link copied